Osteoprotegerin in ST-elevation myocardial infarction: Prognostic impact and association with markers of myocardial damage by magnetic resonance imaging

Fuernau, Georg; Zaehringer, Sebastian; Eitel, Ingo; Waha, Suzanne de; Droppa, Michal; Desch, Steffen; Schuler, Gerhard; Adams, Volker; Thiele, Holger

doi:10.1016/j.ijcard.2012.05.101

Cited by 28 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, as one mediator of inflammation, OPG might be linked to the pathophysiology of CS. Levels of OPG (median 626 ng/L) in the present study were comparable with previous results in STEMI without CS (median 711 ng/L) . Therefore, levels of OPG seem to be not significantly up‐regulated in CS in comparison with other forms of the acute coronary syndrome and therefore may not reflect the presence or severity of CS.…”

Section: Discussionsupporting

confidence: 82%

“…In CS, multiorgan hypoperfusion triggers a systemic inflammatory response due to a complex partly unknown neurohormonal cascade . In the presence of inflammatory triggers such as in acute myocardial infarction, OPG facilitates white blood cell adhesion and migration into blood vessel intima and may therefore promote myocardial reperfusion injury, and also up‐regulates the expression of angiopoietin‐2 . For angiopoietin‐2, a relationship to outcome and severity of CS has been described recently .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Growth‐differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP‐SHOCK II‐trial

Fuernau

Poenisch

Eitel

et al. 2014

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

Aims This study investigates the role of osteoprotegerin (OPG) and growth‐differentiation factor 15 (GDF‐15) as predictors of outcome in cardiogenic shock (CS) complicating acute myocardial infarction. The novel biomarkers OPG and GDF‐15 have shown prognostic impact in various cardiovascular diseases including myocardial infarction. In acute myocardial infarction complicated by CS, the diagnostic and prognostic impact of these biomarkers has not been investigated yet. OPG and GDF‐15 may have additional prognostic impact on early prognosis assessment, being potentially useful for decision‐making in CS. Methods and results In the randomized Intra‐aortic Balloon Pump in cardiogenic Shock II (IABP‐SHOCK II)‐trial, 600 patients with CS complicating acute myocardial infarction undergoing early revascularization were assigned to therapy with or without IABP. Within a pre‐defined substudy, blood samples were collected from 190 patients during PCI. GDF‐15 and OPG serum levels were measured with standard enzyme‐linked immunosorbent assay kits. Patients with GDF‐15 and OPG levels greater than the median showed higher rates of death at 30 days by χ2 testing (OPG, 51% vs. 32%, P = 0.01; GDF‐15, 52% vs. 31%, P = 0.005) and log rank testing [GDF‐15, hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.21–2.94; P = 0.005; OPG, HR 1.74, 95% CI 1.11–2.71; P = 0.01]. Both markers were significantly predictive of 30‐day mortality in univariable logistic regression analysis. In a multivariable logistic stepwise regression model, GDF‐15, TIMI (Thrombolysis In Myocardial Infarction) flow grade <3 after PCI, age, LVEF, and serum lactate remained significant predictors of 30‐day mortality. Conclusion GDF‐15 on admission is a significant independent predictor of short‐term mortality in infarct‐related CS. Trail registration: NCT00491036

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Growth‐differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP‐SHOCK II‐trial

Fuernau

Poenisch

Eitel

et al. 2014

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

show abstract

“…The stress cardiac magnetic resonance care route is an efficient alternative to inpatient care, and can shorten the length of stay in hospital as well as reduce revascularization, recurrent cardiac testing and hospital readmissions in patients with acute chest pain [19]. Moreover, the osteoprotegerin levels in the highest quartile are independent predictors of major adverse cardiovascular events in acute STEMI patients and associated with a greater extent of myocardial damage and lower myocardial salvage by cardiac magnetic resonance [20]. …”

Section: Discussionmentioning

confidence: 99%

Different Prognostic Significance of Cardiac Troponin at Presentation and Peak Cardiac Troponin in Patients with Non-ST Segment Elevation Myocardial Infarction

Siasos

Lazaros

Oikonomou³

et al. 2016

Cardiology

View full text Add to dashboard Cite

Objectives: Non-ST elevation myocardial infarction (NSTEMI) is one of the most common manifestations of acute coronary syndromes (ACS). We evaluated the prognostic role of cardiac troponin I (cTnI) at presentation and peak cardiac troponin I in patients with NSTEMI. Methods: We consecutively enrolled 215 subjects presenting with NSTEMI. Subjects were followed up for 1 year. cTnI at presentation and the peak value of cTnI were measured. The primary end point was defined as cardiovascular death, readmission to hospital with heart failure and new ACS. Results: The subjects who presented the primary end point (49 subjects) had significantly increased values of peak cTnI compared to subjects free of cardiovascular events [7.19 (2.97-21.32) vs. 4.09 (1.18-11.85) ng/l; p = 0.002]. Nevertheless, cTnI at presentation did not differ between subjects who presented the primary end point and those free of events (p = 0.39). Multivariate Cox regression analysis after adjustment for confounders revealed by the univariate analysis showed that for an increase in peak cTnI from 1 to 10 ng/l, there is a 60% anticipated increase in the relative risk to present the primary end point (p = 0.04). Conclusion: These findings documented the different prognostic significance of cTnI at presentation and peak cTnI in patients presenting with NSTEMI, and highlighted the importance of monitoring the levels of cTnI in this high-risk population.

show abstract

“…25 Furthermore, OPG independently predicted deterioration of heart failure that required hospitalization, mainly in older patients with advanced chronic systolic heart failure of ischemic etiology. 26 OPG has also provided independent prognostic information across the range of acute coronary syndromes [27][28][29] and acute ischemic stroke. 30 This is the first study, to date, which showed that OPG also provides important prognostic information in patients with AL amyloidosis.…”

Section: Discussionmentioning

confidence: 99%

Osteoprotegerin is a Significant Prognostic Factor for Overall Survival in Patients with Primary Systemic Amyloidosis Independent of the Mayo Staging

Kastritis

Gavriatopoulos

Eleutherakis‐Papaiakovou

et al. 2015

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Osteoprotegerin in ST-elevation myocardial infarction: Prognostic impact and association with markers of myocardial damage by magnetic resonance imaging

Cited by 28 publications

References 33 publications

Growth‐differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP‐SHOCK II‐trial

Growth‐differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP‐SHOCK II‐trial

Different Prognostic Significance of Cardiac Troponin at Presentation and Peak Cardiac Troponin in Patients with Non-ST Segment Elevation Myocardial Infarction

Osteoprotegerin is a Significant Prognostic Factor for Overall Survival in Patients with Primary Systemic Amyloidosis Independent of the Mayo Staging

Contact Info

Product

Resources

About